Retinopathy of prematurity: Incidence and risk factors

Expert Review of Ophthalmology

Volumn 2, Issue 2, 2007, Pages 267-274

  Mutlu, Fatih Mehmet ^a   Sarici, Serdar ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

birth weight; blindness; gestational age; incidence; retinopathy of prematurity; risk factor

Indexed keywords

EID: 84990869825     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/17469899.2.2.267     Document Type: Article

References (76)

1. Steinkuller PG, Du L, Gilbert C, Foster A, Collins ML, Coats D. Childhood blindness. J. AAPOS 3, 26–32 (1999).
2. Kocur I, Resnikoff S. Visual impairment and blindness in Europe and their prevention. Br. J. Ophthalmol. 86, 716–722 (2002).
3. Gilbert C, Foster A. Childhood blindness in the context of VISION 2020 – the right to sight. Bull. World Health Organ. 79, 227–232 (2001).
4. Terry TL. Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens. I. Preliminary report. Am. J. Ophthalmol. 25, 203–204 (1942).
5. Campbell K. Intensive oxygen therapy as a possible cause of retrolental fibroplasia: a clinical approach. Med. J. Aust. 2, 48–50 (1951).
6. The Committee for the Classification of Retinopathy of Prematurity. An international classification of retinopathy of prematurity. Arch. Ophthalmol. 102, 1130–1134 (1984).
7. Muñoz B, West SK. Blindness and visual impairment in the Americas and the Caribbean. Br. J. Ophthalmol. 86, 498–504 (2002).
8. Kocur I, Kuchynka P, Rodný S, Baráková D, Schwartz EC. Causes of severe visual impairment and blindness in children attending schools for the visually handicapped in the Czech Republic. Br. J. Ophthalmol. 85, 1149–1152 (2001).
9. Gopal L, Sharma T, Shanmugam M et al. Surgery for stage 5 retinopathy of prematurity: the learning curve and evolving technique. Indian J. Ophthalmol. 48, 101–106 (2000).
10. Vohr BR, Wright LL, Dusick AM et al. Center differences and outcomes of extremely low birth weight infants. Pediatrics 113, 781–789 (2004).
11. Lee SK, McMillan DD, Ohlsson A et al. Variations in practice and outcomes in the Canadian NICU Network: 1996–1997. Pediatrics 106, 1070–1079 (2000).
12. Palmer EA, Flynn JT, Hardy RJ et al. Incidence and early course of retinopathy of prematurity. Ophthalmology 98, 1628–1640 (1991).
13. Brown MS, Baron AE, France EK, Hamman RF. Association between higher cumulative doses of recombinant erythropoietin and risk for retinopathy of prematurity. J. AAPOS 10, 143–149 (2006).
14. Blair BM, O’Halloran HS, Pauly TH, Stevens JL. Decreased incidence of retinopathy of prematurity, 1995–1997. J. AAPOS 5, 118–122 (2001).
15. Mathew MR, Fern AI, Hill R. Retinopathy of prematurity: are we screening too many babies? Eye 16, 538–542 (2002).
16. Shah VA, Yeo CL, Ling YL, Ho LY. Incidence, risk factors of retinopathy of prematurity among very low birth weight infants in Singapore. Ann. Acad. Med. Singapore 34, 169–178 (2005).
17. Phan MH, Nguyen PN, Reynolds JD. Incidence and severity of retinopathy of prematurity in Vietnam, a developing middle-income country. J. Pediatr. Ophthalmol. Strabismus 40, 208–212 (2003).
18. Larsson E, Carle-Petrelius B, Cernerud G, Ots L, Wallin A, Holmstrom G. Incidence of ROP in two consecutive Swedish population based studies. Br. J. Ophthalmol. 86, 1122–1126 (2002).
19. Mayet I, Cockinos C. Retinopathy of prematurity in South Africans at a tertiary hospital: a prospective study. Eye 20, 29–31 (2006).
20. Delport SD, Swanepoel JC, Odendaal PJ, Roux P. Incidence of retinopathy of prematurity in very-low-birth-weight infants born at Kalafong Hospital, Pretoria. S. Afr. Med. J. 92, 986–990 (2002).
21. Yanovitch TL, Siatkowski RM, McCaffree M, Corff KE. Retinopathy of prematurity in infants with birth weight>or=1250 grams – incidence, severity, and screening guideline cost-analysis. J. AAPOS 10, 128–134 (2006).
22. Mutlu FM, Altinsoy HI, Mumcuoglu T et al. Frequency and risk factor analysis for retinopathy of prematurity: a multivariate statistical analysis. J. Pediatr. Ophthalmol. Strabismus (In press).
23. Early Treatment for Retinopathy of Prematurity Cooperative Group. Results of the Early Treatment for Retinopathy of Prematurity Randomized Trial: revised indications for the treatment of retinopathy of prematurity. Arch. Ophthalmol. 121, 1684–1696 (2003).
24. Early Treatment for Retinopathy of Prematurity Cooperative Group. The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study. Pediatrics 116, 15–23 (2005).
25. Quinn GE. What do we do about ROP in larger birth weight babies? Br. J. Ophthalmol. 86, 1072–1073 (2002).
26. Reynolds JD, Dobson V, Quinn GE et al. Evidence-based screening criteria for retinopathy of prematurity: natural history data from the CRYO-ROP and LIGHT-ROP studies. Arch. Ophthalmol. 120, 1470–1476 (2003).
27. Section on Ophthalmology American Academy of Pediatrics; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 117, 572–576 (2006).
28. Jalali S, Matalia J, Hussain A, Anand R. Modification of screening criteria for retinopathy of prematurity in India and other middle-income countries. Am. J. Ophthalmol. 141, 966–968 (2006).
29. Chow LC, Wright KW, Sola A; CSMC Oxygen Administration Study Group. Can changes in clinical practice decrease the incidence of severe retinopathy of prematurity in very low birth weight infants? Pediatrics 111, 339–345 (2003).
30. Rowlands E, Ionides AC, Chinn S, Mackinnon H, Davey CC. Reduced incidence of retinopathy of prematurity. Br. J. Ophthalmol. 85, 933–935 (2001).
31. Allegaert K, de Coen K, Devlieger H; EpiBel Study Group. Threshold retinopathy at threshold of viability: the EpiBel study. Br. J. Ophthalmol. 88, 239–242 (2004).
32. Fielder AR, Posner EJ. Neonatal ophthalmology. In: Roberton’s Textbook of Neonatology. Rennie JM (Ed.). Elsevier Churchill Livingstone, London, UK 835–850 (2005).
33. Schaffer DB, Palmer EA, Plotsky DF et al. Prognostic factors in the natural course of retinopathy of prematurity. THA Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology 100, 230–237 (1993).
34. Akkoyun I, Oto S, Yilmaz G et al. Risk factors in the development of mild and severe retinopathy of prematurity. J. AAPOS 10, 449–453 (2006).
35. Vanderveen DK, Mansfield TA, Eichenwald EC. Lower oxygen saturation alarm limits decrease the severity of retinopathy of prematurity. J. AAPOS 10, 445–448 (2006).
36. York JR, Landers S, Kirby RS, Arbogast PG, Penn JS. Arterial oxygen fluctuation and retinopathy of prematurity in very-low-birth-weight infants. J. Perinatol. 24, 82–87 (2004).
37. McColm JR, Geisen P, Hartnett ME. VEGF isoforms and their expression after a single episode of hypoxia or repeated oxygen fluctuations between hyperoxia and hypoxia: relevance to clinical ROP. Mol. Vis. 10, 512–520 (2004).
38. The STOP-ROP Multicenter Study Group. Supplemental therapeutic oxygen for Pretheshold retinopathy of prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics 105, 295–310 (2000).
39. Lubetzky R, Stolovitch C, Dollberg S, Mimouni FB, Salomon M, Mandel D. Nucleated red blood cells in preterm infants with retinopathy of prematurity. Pediatrics 116, e619 –e622 (2005).
40. Shohat M, Reisner SH, Krikler R, Nissenkorn I, Yassur Y, Ben-Sira I. Retinopathy of prematurity: incidence and risk factors. Pediatrics 72, 159–163 (1983).
41. Brown DR, Milley JR, Ripepi UJ et al. Retinopathy of prematurity. Risk factors in a five-year cohort of critically ill premature neonates. Am. J. Dis. Child. 141, 154–160 (1987).
42. Smith LE. Pathogenesis of retinopathy of prematurity. Growth Horm. IGF Res. 14, 140–144 (2004).
43. Smith LE. IGF-I and retinopathy of prematurity in the preterm infant. Biol. Neonate 88, 237–244 (2005).
44. Hellström A, Engström E, Hard AL et al. Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics 112, 1016–1020 (2003).
45. Ozkan H, Duman N, Kumral A et al. Inhibition of vascular endothelial growth factor-induced retinal neovascularization by retinoic acid in experimental retinopathy of prematurity. Physiol. Res. 55, 267–275 (2006).
46. Bizzarro MJ, Hussain N, Jonsson B et al. Genetic susceptibility to retinopathy of prematurity. Pediatrics 118, 1858–1863 (2006).
47. Vannay A, Dunai G, Banyasz I et al. Association of genetic polymorphisms of vascular endothelial growth factor and risk for proliferative retinopathy of prematurity. Pediatr. Res. 57, 396–398 (2005).
48. Cooke WI, Drury JA, Mountford R, Clark D. Genetic polymorphisms and retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 45, 1712–1715 (2004).
49. Yang MB, Donovan EF, Wagge JR. Race, gender, and clinical risk index for babies (CRIB) score as predictors of severe retinopathy of prematurity. J. AAPOS 10, 253–261 (2006).
50. Tadesse M, Dhanireddy R, Mittal M, Higgins RD. Race, candida sepsis, and retinopathy of prematurity. Biol. Neonate 81, 86–90 (2002).
51. Hutcheson KA, Paluru PC, Bernstein SL et al. Norrie disease gene sequence variants in an ethnically diverse population with retinopathy of prematurity. Mol. Vis. 14, 501–508 (2005).
52. Hiraoka M, Berinstein DM, Trese MT, Shastry BS. Insertion and deletion mutations in the dinucleotide repeat region of the Norrie disease gene in patients with advanced retinopathy of prematurity. J. Hum. Genet. 46, 178–181 (2001).
53. Downey LM, Keen TJ, Roberts E, Mansfield DC, Bamashmus M, Inglehearn CF. A new locus for autosomal dominant familial exudative vitreoretinopathy maps to chromosome 11p12–13. Am. J. Hum. Genet. 68, 778–781 (2001).
54. Console V, Gagliardi L, De Giorgi A, De Ponti E. Retinopathy of prematurity and antenatal corticosteroids. The Italian ROP Study Group. Acta Biomed. Ateneo. Parmense 68, 75–79 (1997).
55. Haroon Parupia MF, Dhanireddy R. Association of postnatal dexamethasone use and fungal sepsis in the development of severe retinopathy of prematurity and progression to laser therapy in extremely low-birth-weight infants. J. Perinatol. 21, 242–247 (2001).
56. Schmidt B, Davis P, Moddemann D et al. Long-term effects of indomethacin prophylaxis in extremely low-birth-weight infants. N. Engl. J. Med. 344, 1966–1972 (2001).
57. Sharma J, Barr SM, Geng Y, Yun Y, Higgins RD. Ibuprofen improves oxygen-induced retinopathy in a mouse model. Curr. Eye Res. 27, 309–314 (2003).
58. Van Overmeire B, Allegaert K, Casaer A et al. Prophylactic ibuprofen in premature infants: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 364, 1945–1949 (2004).
59. Hosono S, Ohno T, Kimoto T et al. No clinical correlation between bilirubin levels and severity of retinopathy of prematurity. J. Pediatr. Ophthalmol. Strabismus 39, 151–156 (2002).
60. Milner JD, Aly HZ, Ward LB, El-Mohandes A. Does elevated peak bilirubin protect from retinopathy of prematurity in very low birthweight infants. J. Perinatol. 23, 208–211 (2003).
61. Reynolds JD, Hardy RJ, Kennedy KA, Spencer R, van Heuven WA, Fielder AR. Lack of efficacy of light reduction in preventing retinopathy of prematurity. Light Reduction in Retinopathy of Prematurity (LIGHT-ROP) Cooperative Group. N. Engl. J. Med. 338, 1572–1576 (1998).
62. Phelps DL, Watts JL. Early light reduction for preventing retinopathy of prematurity in very low birth weight infants. Cochrane Database Syst. Rev. 1, CD0000122 (2001).
63. Inder TE, Graham PJ, Winterbourn CC, Austin NC, Darlow BA. Plasma vitamin A levels in the very low birth weight infant: relationship to respiratory outcome. Early Hum. Dev. 52, 155–168 (1998).
64. Shenai JP, Kennedy KA, Chytil F, Stahlman MT. Clinical trial of vitamin A supplementation in infants susceptible to bronchopulmonary dysplasia. J. Pediatr. 111, 269–277 (1987).
65. Ambalavanan N, Wu TJ, Tyson JE, Kennedy KA, Roane C, Carlo WA. A comparison of three vitamin A dosing regimes in extremely-low-birth-weight infants. J. Pediatr. 142, 656–661 (2003).
66. Darlow BA, Graham PJ. Vitamin A supplementation for preventing morbidity and mortality in very low birthweight infants. Cochrane Database Syst. Rev. 4, CD000501 (2002).
67. Raju TK, Langenberg P, Bhutani V et al. Vitamin E prophylaxis to reduce retinopathy of prematurity: a reappraisal of published trials. J. Pediatr. 131, 844–850 (1997).
68. Law MR, Wijewardene K, Wald NJ. Is routine vitamin E administration justified in very low-birthweight infants? Dev. Med. Child Neurol. 32, 442–450 (1990).
69. Friedman CA, McVey J, Borne MJ et al. Relationship between serum inositol concentration and development of retinopathy of prematurity: a prospective study. J. Pediatr. Ophthalmol. Strabismus 37, 79–86 (2000).
70. Englert JA, Saunders RA, Purohit D, Hulsey TC, Ebeling M. The effect of anemia on retinopathy of prematurity in extremely low birth weight infants. J. Perinatol. 21, 21–26 (2001).
71. Pennefather PM, Tin W. Ocular abnormalities associated with cerebral palsy after preterm birth. Eye 14, 78–81 (2000).
72. Wallace DK, Kylstra JA, Phillips SJ, Hall JG. Poor postnatal weight gain: a risk factor for severe retinopathy of prematurity. J. AAPOS 4, 343–347 (2000).
73. Karlowicz MG, Giannone PJ, Pestian J, Morrow AL, Shults J. Does candidemia predict threshold retinopathy of prematurity in extremely low birth weight (
74. Seiberth V, Linderkamp O. Risk factors in retinopathy of prematurity. A multivariate statistical analysis. Ophthalmologica 214, 131–135 (2000).
75. Watts P, Adams GG. In vitro fertilisation and stage 3 retinopathy of prematurity. Eye 14, 330–333 (2000).
76. United Nations Development Programme. Human Development Report, 2004. http://hdr.undp.org/reports